Is MNOV or MGNX more profitable?

MacroGenics has a net margin of -44.79% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MediciNova -1,962.98% -27.28% -25.24% MacroGenics -44.79% -147.80% -28.40%

Do analysts recommend NLTX or MNOV?

MediciNova has a consensus price target of $7.50, indicating a potential upside of 466.04%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

MediciNova (MNOV) Competitors

$1.32 +0.01 (+0.38%)

As of 01:38 PM Eastern

Compare

MNOV vs. TRDA, FBRX, MGNX, NLTX, and NVCT

Should you buy MediciNova stock or one of its competitors? MarketBeat compares MediciNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediciNova include Entrada Therapeutics (TRDA), Forte Biosciences (FBRX), MacroGenics (MGNX), Neoleukin Therapeutics (NLTX), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

How does MediciNova compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

MediciNova has a net margin of -1,962.98% compared to Entrada Therapeutics' net margin of -2,895.05%. MediciNova's return on equity of -27.28% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
MediciNova	-1,962.98%	-27.28%	-25.24%

Entrada Therapeutics presently has a consensus price target of $18.25, suggesting a potential upside of 164.68%. MediciNova has a consensus price target of $7.50, suggesting a potential upside of 466.04%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

MediciNova has lower revenue, but higher earnings than Entrada Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.53	-$143.75M	-$3.99	N/A
MediciNova	$410K	159.06	-$12M	-$0.23	N/A

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 6 more articles in the media than MediciNova. MarketBeat recorded 6 mentions for Entrada Therapeutics and 0 mentions for MediciNova. MediciNova's average media sentiment score of 1.89 beat Entrada Therapeutics' score of 0.49 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
MediciNova	Very Positive

Summary

MediciNova beats Entrada Therapeutics on 13 of the 17 factors compared between the two stocks.

How does MediciNova compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Forte Biosciences currently has a consensus target price of $67.00, indicating a potential upside of 307.29%. MediciNova has a consensus target price of $7.50, indicating a potential upside of 466.04%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Forte Biosciences has a beta of 2.87, indicating that its share price is 187% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Forte Biosciences has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
MediciNova	-1,962.98%	-27.28%	-25.24%

In the previous week, MediciNova's average media sentiment score of 1.89 beat Forte Biosciences' score of 1.87 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Very Positive
MediciNova	Very Positive

MediciNova has higher revenue and earnings than Forte Biosciences. MediciNova is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
MediciNova	$410K	159.06	-$12M	-$0.23	N/A

Summary

MediciNova beats Forte Biosciences on 10 of the 14 factors compared between the two stocks.

How does MediciNova compare to MacroGenics?

MediciNova (NASDAQ:MNOV) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

In the previous week, MacroGenics had 1 more articles in the media than MediciNova. MarketBeat recorded 1 mentions for MacroGenics and 0 mentions for MediciNova. MediciNova's average media sentiment score of 1.89 beat MacroGenics' score of 0.31 indicating that MediciNova is being referred to more favorably in the media.

Company	Overall Sentiment
MediciNova	Very Positive
MacroGenics	Neutral

MediciNova has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

MediciNova has higher earnings, but lower revenue than MacroGenics. MediciNova is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	159.06	-$12M	-$0.23	N/A
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MediciNova currently has a consensus price target of $7.50, suggesting a potential upside of 466.04%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 28.35%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts plainly believe MediciNova is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

MacroGenics has a net margin of -44.79% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
MacroGenics	-44.79%	-147.80%	-28.40%

Summary

MediciNova beats MacroGenics on 10 of the 16 factors compared between the two stocks.

How does MediciNova compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Neoleukin Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
MediciNova	-1,962.98%	-27.28%	-25.24%

In the previous week, MediciNova's average media sentiment score of 1.89 beat Neoleukin Therapeutics' score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
MediciNova	Very Positive

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MediciNova has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
MediciNova	$410K	159.06	-$12M	-$0.23	N/A

MediciNova has a consensus price target of $7.50, indicating a potential upside of 466.04%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

MediciNova beats Neoleukin Therapeutics on 12 of the 15 factors compared between the two stocks.

How does MediciNova compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Nuvectis Pharma had 1 more articles in the media than MediciNova. MarketBeat recorded 1 mentions for Nuvectis Pharma and 0 mentions for MediciNova. MediciNova's average media sentiment score of 1.89 beat Nuvectis Pharma's score of 0.93 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Positive
MediciNova	Very Positive

Nuvectis Pharma has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
MediciNova	-1,962.98%	-27.28%	-25.24%

MediciNova has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
MediciNova	$410K	159.06	-$12M	-$0.23	N/A

Nuvectis Pharma currently has a consensus target price of $10.00, suggesting a potential upside of 6.73%. MediciNova has a consensus target price of $7.50, suggesting a potential upside of 466.04%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nuvectis Pharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

MediciNova beats Nuvectis Pharma on 12 of the 16 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$65.22M	$3.34B	$6.43B	$12.45B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-5.76	18.80	23.85	24.37
Price / Sales	159.06	320.09	522.03	117.40
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	1.56	6.83	10.04	6.75
Net Income	-$12M	$24.09M	$3.56B	$337.03M
7 Day Performance	-3.28%	-2.36%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-7.34%	48.79%	28.88%	34.01%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	3.633 of 5 stars	$1.33 +0.4%	$7.50 +466.0%	-5.7%	$65.22M	$410K	N/A	10	Positive News
TRDA Entrada Therapeutics	4.1285 of 5 stars	$6.64 -3.9%	$18.25 +174.8%	-20.1%	$268.25M	$25.42M	N/A	110
FBRX Forte Biosciences	2.0074 of 5 stars	$18.17 -5.6%	$67.00 +268.7%	+78.0%	$267.16M	N/A	N/A	5	Positive News
MGNX MacroGenics	2.3034 of 5 stars	$4.05 -2.2%	$5.50 +35.8%	+178.1%	$263.15M	$149.50M	N/A	430	Short Interest Increase
NLTX Neoleukin Therapeutics	N/A	$27.54 -2.8%	N/A	+47.3%	$258.82M	N/A	N/A	90	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. TRDA, FBRX, MGNX, NLTX, and NVCT

How does MediciNova compare to Entrada Therapeutics?

Summary

How does MediciNova compare to Forte Biosciences?

Summary

How does MediciNova compare to MacroGenics?

Summary

How does MediciNova compare to Neoleukin Therapeutics?

Summary

How does MediciNova compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. TRDA, FBRX, MGNX, NLTX, and NVCT

How does MediciNova compare to Entrada Therapeutics?

Is TRDA or MNOV more profitable?

Do analysts recommend TRDA or MNOV?

Which has better valuation & earnings, TRDA or MNOV?

Do institutionals & insiders hold more shares of TRDA or MNOV?

Which has more volatility & risk, TRDA or MNOV?

Does the media prefer TRDA or MNOV?

Summary

How does MediciNova compare to Forte Biosciences?

Do analysts rate FBRX or MNOV?

Which has more risk & volatility, FBRX or MNOV?

Do insiders & institutionals believe in FBRX or MNOV?

Is FBRX or MNOV more profitable?

Does the media refer more to FBRX or MNOV?

Which has higher earnings and valuation, FBRX or MNOV?

Summary

How does MediciNova compare to MacroGenics?

Does the media favor MNOV or MGNX?

Which has more risk and volatility, MNOV or MGNX?

Which has preferable earnings and valuation, MNOV or MGNX?

Do institutionals and insiders hold more shares of MNOV or MGNX?

Do analysts prefer MNOV or MGNX?

Is MNOV or MGNX more profitable?

Summary

How does MediciNova compare to Neoleukin Therapeutics?

Is NLTX or MNOV more profitable?

Does the media refer more to NLTX or MNOV?

Which has more volatility & risk, NLTX or MNOV?

Do insiders and institutionals have more ownership in NLTX or MNOV?

Which has stronger valuation and earnings, NLTX or MNOV?

Do analysts recommend NLTX or MNOV?

Summary

How does MediciNova compare to Nuvectis Pharma?

Does the media prefer NVCT or MNOV?

Is NVCT or MNOV more profitable?

Which has stronger valuation and earnings, NVCT or MNOV?

Do analysts rate NVCT or MNOV?

Do institutionals and insiders hold more shares of NVCT or MNOV?

Which has more volatility & risk, NVCT or MNOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools